SEARCH
Home
News
Fortune 500
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Great Place to Work
Tech
AI
Innovation
Cybersecurity
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Success
Future of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Analytics
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Home
News
FORTUNE 500
FORTUNE 500
FORTUNE SEA 500
Fortune 500 Europe
Fortune Global 500
Fortune China 500
Great Place to Work
Tech
Tech
AI
Innovation
Cybersecurity
Finance
Finance
Personal Finance
Real Estate
Economy
Banking
Investing
Crypto
Leadership
Leadership
Success
Future of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Rankings
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Asia
Europe
Analytics
home
home
Pharmaceutical Industry
Pharmaceutical Industry
Page 11 of 100
Conferences
Only an AI breakthrough can help humans live longer, argues drug developer: ‘We need a ChatGPT moment in longevity’
By
Christiaan Hetzner
July 31, 2024
Commentary
I’m an obesity medicine doctor and I’ve been on weight-loss drugs like Ozempic for a decade. Here’s why I think they aren’t a fad
By
Angela Fitch
July 30, 2024
Finance
Swiss pharma giant Roche is ‘fast-tracking’ development of an experimental Wegovy challenger pill for weight loss
By
Prarthana Prakash
July 29, 2024
Finance
A CEO abruptly resigned from a board after leaked emails reportedly showed inappropriate influence
By
Marion Halftermeyer
and
Bloomberg
July 26, 2024
Health
Sergey Brin is using money from selling his Tesla shares to bankroll a startup developing hallucinogenic mental-health treatments
By
Marco Quiroz-Gutierrez
July 23, 2024
Retail
An obesity pill study tested on just 25 patients led to a stunning $16.8 billion increase in Swiss drugmaker Roche’s market value
By
Naomi Kresge
,
Lisa Pham
and
Bloomberg
July 23, 2024
Health
Pharma giant Pfizer is trying to cash in on the weight loss drug craze with a new pill that could be a welcome needle-free alternative to pesky GLP-1 shots
By
Damian Garde
and
Bloomberg
July 11, 2024
Commentary
Why investing in places like Birmingham, Alabama is key to securing U.S. biotech dominance as China tries to close the gap
By
Katie Britt
,
Terri Sewell
,
Kay Ivey
and
Randall Woodfin
July 3, 2024
Commentary
Alzheimer’s made my mom unable to recognize her grandkids. Breakthroughs too late for her can change the disease’s trajectory—if diagnosis and treatment start early
By
Anne E. White
July 2, 2024
Health
Fake Ozempic and Wegovy are flooding the market. Here are 4 steps to avoid dangerous counterfeit weight loss drugs
By
Amanda Loudin
June 28, 2024
Tech
Meta axed his AI biology research team. Now this ‘Meta AI mafia’ member’s new startup has $142 million to chase his protein-generating dream
By
Sharon Goldman
June 25, 2024
Commentary
‘A head-in-the-sand approach’: The U.S. strategic drug stockpile is inadequate for a bird flu outbreak
By
Carolyn Barber
June 24, 2024
Leadership
Forget expensive coaches, Paul Hudson, CEO of Sanofi turns to his three children for advice: ‘Through their eyes I get a glimpse into what the future looks like for the next generation’
By
Peter Vanham
June 20, 2024
Retail
Ozempic is 1,300% more expensive in the U.S. vs the U.K.—so the boss of Novo Nordisk is being hauled in front of Bernie Sanders to explain why
By
Ryan Hogg
June 17, 2024
Health
Mold colonies and liquid-flooded air purifiers: CVS sourced medication from tainted factories—and it has twice the amount of recalls on store-brand drugs than competitors
By
Sasha Rogelberg
June 11, 2024
Most Popular
Success
Meet a 23-year-old electrician who was a 'good student' but skipped college to join Gen Z's blue-collar revolution. He...
By
Nick Lichtenberg
Success
Billionaire who sold two companies to Coca-Cola says he tries to convince people not to become entrepreneurs: 'Every...
By
Dave Smith
AI
Ray Dalio calls for wealth 'redistribution policy' when AI and humanoid robots start to benefit the 1% to 10% more than...
By
Nick Lichtenberg